Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

44.26 +0.32 (+0.73%)
Official Closing Price Updated: 4:10 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
42 43 Next >
Oil Output Cut May Tip Global Economy Into Recession, Elon Musk's Starship's First Space Tourist, Alphabet Approves Distribution Of Trump's Truth Social App: Top Stories Thursday, Oct. 13
Reuters 
Via Benzinga
GSK Touts 'Exceptional Results' From RSV Vaccine Candidate In Older Adults
 
Via Benzinga
Is Pfizer Stock Still Worth Buying After the Pandemic?
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations. 
Via MarketBeat
FDA Approves GSK's Whooping Cough Vaccine During Pregnancy For Prevention In Infants
 
Via Benzinga
Unilever CEO Alan Jope To Retire Next Year
 
Via Benzinga
Want $1,000 in Passive Income? Don't Make These 3 Mistakes
It's easy to get poor returns if you don't diversify your portfolio and carefully calibrate your expectations. 
Via The Motley Fool
3 Dirt-Cheap Stocks That Could Soar 48% to 68%, According to Wall Street
These stocks could attract both value and growth investors. 
Via The Motley Fool
AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial
 
Via Benzinga
DEA-Licensed Pharmaceutical Cannabis Research Company Announces $20M Series A Funding Round
The Biopharmaceutical Research Company (BRC), an active DEA pharmaceutical cannabis license holder, announced the completion of a $20 million Series A fundraise, that will enable the company to scale... 
Via Benzinga
The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On It
BARDA will pay Vir up to $1 billion to develop its experimental treatment. 
Via Investor's Business Daily
This Is the Best Time to Buy These 7 Long-Term Dividend Stocks
Investors want long-term dividend stocks to buy as interest rates rise. 
Via InvestorPlace
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
7 Consumer Stocks to Sell Before They Die
These are the top consumer stocks to sell before things get worse. These companies are struggling with issues that will take years to fix. 
Via InvestorPlace
2 High Yielders Decimated By The Russia-Ukraine War: Is Now The Time To Buy?
As the Russia-Ukraine war moves forward, the European economy remains in a fragile state. 
Via Benzinga
iPhone 14 Popular In China?, Netflix May Lose Comics, Elon Musk's Starlink Slows, Byron Allen Faces $10B Lawsuit And More Top Financial Media Stories Monday, Sept. 26
Bloomberg 
Via Benzinga
Burberry Finance Chief Joins GSK As First Woman CFO
 
Via Benzinga
7 Stocks to Buy That Can Soar in Good Times or in Bad
Investors looking for growth stocks to buy that are largely immune from broader economic woes have come to the right place. 
Via InvestorPlace
Spero Therapeutics (NASDAQ: SPRO) Enters into Exclusive Licensing Agreement with GSK (NYSE: GSK) for the Commercialization of Tebipenem HBr
Spero Therapeutics, Inc. (NASDAQ: SPRO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement
Spero Therapeutics (SPRO) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (GSK). 
Via InvestorPlace
Top Financial Media Stories Thursday, September 22: Facebook Sued For Bypassing Apple Privacy Rules, Walmart Slows Hiring Plans Ahead Of Holiday Season, China Blames US For Northwestern Polytechnical University Hack And More..
Reuters 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for an overview of the biggest pre-market stock movers for Thursday and all the news behind this morning's movement. 
Via InvestorPlace
Spero Therapeutics Stock More Than Doubles On GSK Pact For Its Lead Antibiotic
GSK Plc (NASDAQ: GSK) has entered into an exclusive license agreement for Spero Therapeutics Inc's (NASDAQ: SPRO) late-stage antibiotic asset, tebipenem HBr.  
Via Benzinga
Jim Cramer Says This Stock Is A 'Great Spec And I Usually Don't Say That,' And Analysts Approve
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Certara, Inc. (NASDAQ: CERT) is not bad and also not losing money. "I think it’s a great spec, and I usually don’t say that," he added. 
Via Benzinga
3 Biotech Stocks to Buy Now for Extraordinary Gains
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market. 
Via InvestorPlace
Haleon Clocks Double Digit Growth In Interim Revenue, Profits; Sticks To Annual Guidance
 
Via Benzinga
Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer
 
Via Benzinga
Recent Stock Purchase September 2022
I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines. 
Via Talk Markets
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
 
Via Benzinga
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
Via Benzinga
Pfizer's Pentavalent Meningococcal Vaccine Candidate Shows Efficacy In Adolescents
 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback